Article
Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2).
Rheumatology (Oxford, England) - 1 Sept 2021
Cooray Samantha, Omyinmi Ebun, Hong Ying, Papadopoulou Charalampia, Harper Lorraine, Al-Abadi Eslam, Goel Ruchika, Dubey Shirish, Wood Mark, Jolles Stephen, Berg Stefan, Ekelund Maria, Armon Kate, Eleftheriou Despina, Brogan Paul A
Abstract excerpt
OBJECTIVE: To evaluate the impact of anti-Tumour Necrosis Factor-α (anti-TNF) treatment on the occurrence of vasculitic ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). METHODS: A retrospective analysis of DADA2 patients referred from six centres to Great Ormond Street Hospital for Children was conducted. Ischaemic events, vasculitic disease activity, biochemical, immunological, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.